Latest BAKER BROS. ADVISORS LP Stock Portfolio

BAKER BROS. ADVISORS LP Performance:

2024 Q3: 16.93%YTD: 4.42%2023: -0.24%

Performance for 2024 Q3 is 16.93%, and YTD is 4.42%, and 2023 is -0.24%.

About BAKER BROS. ADVISORS LP and 13F Hedge Fund Stock Holdings

BAKER BROS. ADVISORS LP is a hedge fund based in NEW YORK, NY. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $23.2 Billions. In it's latest 13F Holdings report, BAKER BROS. ADVISORS LP reported an equity portfolio of $9.6 Billions as of 30 Sep, 2024.

The top stock holdings of BAKER BROS. ADVISORS LP are BGNE, INCY, ACAD. The fund has invested 24.6% of it's portfolio in BEIGENE, LTD. and 21.1% of portfolio in INCYTE CORPORATION.

The fund managers got completely rid off CEREVEL THERAPEUTICS HOLDINGS, INC. (CERE), ATHIRA PHARMA, INC. (ATHA) and TALIS BIOMEDICAL CORPORATION (TLIS) stocks. They significantly reduced their stock positions in NEWAMSTERDAM PHARMA COMPANY N.V. (NAMS) and HOOKIPA PHARMA INC. (HOOK). BAKER BROS. ADVISORS LP opened new stock positions in BICARA THERAPEUTICS INC., ARVINAS, INC. (ARVN) and IONIS PHARMACEUTICALS, INC. (IONS). The fund showed a lot of confidence in some stocks as they added substantially to CRISPR THERAPEUTICS AG (CRSP), SKYE BIOSCIENCE, INC. (SKYE) and IMMUNOVANT, INC. (IMVT).

BAKER BROS. ADVISORS LP Annual Return Estimates Vs S&P 500

Our best estimate is that BAKER BROS. ADVISORS LP made a return of 16.93% in the last quarter. In trailing 12 months, it's portfolio return was 17.14%.

New Buys

Ticker	$ Bought
bicara therapeutics inc.	21,225,000
arvinas, inc.	9,989,340
ionis pharmaceuticals, inc.	8,952,210
structure therapeutics inc.	3,752,600
wave life sciences ltd.	2,821,320
aligos therapeutics, inc.	719,256

New stocks bought by BAKER BROS. ADVISORS LP

Additions

Ticker	% Inc.
crispr therapeutics ag	743
skye bioscience, inc.	186
immunovant, inc.	163
praxis precision medicines, inc.	145
centessa pharmaceuticals plc	123
generation bio co.	61.14
insmed incorporated	23.49
xencor, inc.	22.92

Additions to existing portfolio by BAKER BROS. ADVISORS LP

Reductions

Ticker	% Reduced
newamsterdam pharma company n.v.	-0.12
hookipa pharma inc.	0.00

BAKER BROS. ADVISORS LP reduced stake in above stock

Sold off

Ticker	$ Sold
insmed incorporated	-56,192,300
athira pharma, inc.	-8,357,590
adaptimmune therapeutics plc	-2,284,870
achilles therapeutics plc	-903,645
cerevel therapeutics holdings, inc.	-27,951,900
talis biomedical corporation	-4,402,990
sage therapeutics, inc.	-1,857,340
aligos therapeutics, inc.	-726,740

BAKER BROS. ADVISORS LP got rid off the above stocks

Sector Distribution

BAKER BROS. ADVISORS LP has about 96.7% of it's holdings in Healthcare sector.

Sector	%
Healthcare	96.7
Others	3.3

Market Cap. Distribution

BAKER BROS. ADVISORS LP has about 49.5% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	27.6
MEGA-CAP	24.8
LARGE-CAP	24.7
SMALL-CAP	17.2
UNALLOCATED	3.8
MICRO-CAP	1.8

Stocks belong to which Index?

About 64.8% of the stocks held by BAKER BROS. ADVISORS LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	43.5
Others	35.2
S&P 500	21.3

Top 5 Winners (%)		%
ALGS	aligos therapeutics, inc.	1474.5 %
IGMS	igm biosciences, inc.	140.7 %
BMEA	biomea fusion, inc.	124.4 %
CMPX	compass therapeutics, inc.	84.0 %
FHTX	foghorn therapeutics inc.	61.9 %

Top 5 Winners ($)		$
BGNE	beigene, ltd.	865.0 M
INCY	incyte corporation	168.4 M
KYMR	kymera therapeutics, inc.	104.8 M
RYTM	rhythm pharmaceuticals, inc.	72.5 M
EWTX	edgewise therapeutics, inc.	50.7 M

Top 5 Losers (%)		%
PRLD	prelude therapeutics inc.	-45.7 %
SRZN	surrozen, inc.	-38.0 %
IPSC	century therapeutics, inc.	-32.9 %
HOOK	hookipa pharma inc.	-27.3 %
MDGL	madrigal pharmaceuticals, inc.	-24.3 %

Top 5 Losers ($)		$
MDGL	madrigal pharmaceuticals, inc.	-134.2 M
ACAD	acadia pharmaceuticals inc.	-37.3 M
PRLD	prelude therapeutics inc.	-17.6 M
ABCL	abcellera biologics inc.	-9.9 M
STOK	stoke therapeutics, inc.	-5.3 M

BAKER BROS. ADVISORS LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS LP has 92 stocks in it's portfolio. About 77.9% of the portfolio is in top 10 stocks. MDGL proved to be the most loss making stock for the portfolio. BGNE was the most profitable stock for BAKER BROS. ADVISORS LP last quarter.

Last Reported on: 14 Nov, 2024

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ABCL	abcellera biologics inc.	0.74	27,525,600	71,566,700	unchanged	0.00

ACAD	acadia pharmaceuticals inc.	6.84	42,877,900	659,462,000	unchanged	0.00

ACHL	achilles therapeutics plc	0.00	0.00	0.00	sold off	-100

ADAP	adaptimmune therapeutics plc	0.00	0.00	0.00	sold off	-100

AKRO	akero therapeutics, inc.	0.33	1,097,080	31,475,300	unchanged	0.00

ALEC	alector, inc.	0.04	927,264	4,321,050	unchanged	0.00

ALGS	aligos therapeutics, inc.	0.01	83,055	719,256	new

ALGS	aligos therapeutics, inc.	0.00	0.00	0.00	sold off	-100

ALKS	alkermes plc	1.21	4,181,750	117,047,000	unchanged	0.00

ARCT	arcturus therapeutics holdings inc.	0.04	151,329	3,512,350	unchanged	0.00

ARVN	arvinas, inc.	0.10	405,576	9,989,340	new

ATHA	athira pharma, inc.	0.00	0.00	0.00	sold off	-100

AVTE	aerovate therapeutics, inc.	0.01	628,939	1,314,480	unchanged	0.00

BCRX	biocryst pharmaceuticals, inc.	0.01	75,778	575,913	unchanged	0.00

BCYC	bicycle therapeutics plc	2.20	9,399,960	212,721,000	unchanged	0.00

BGNE	beigene, ltd.	24.59	10,568,900	2,372,820,000	unchanged	0.00

BMEA	biomea fusion, inc.	0.22	2,108,950	21,300,400	unchanged	0.00

CELC	celcuity inc.	0.29	1,874,980	27,955,900	unchanged	0.00

CERE	cerevel therapeutics holdings, inc.	0.00	0.00	0.00	sold off	-100

CERS	cerus corporation	0.35	19,477,300	33,890,600	unchanged	0.00